Hemoperfusion in Covid 19

Phase 2

Recruiting

• Conditions: COVID19.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20210718051922N1
• Lead Sponsor: Shahre-kord University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with severe progressive pulmonary involvement
Have a positive PCR test
Patients who are currently under mechanical ventilation or will need it in the near future.

Exclusion Criteria

Patients with shock symptoms
Patients with multiple organ failure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality. Timepoint: End of study. Method of measurement: Patient file.;Number of hospitalization days. Timepoint: End of study. Method of measurement: Patient file.;CT scan indexes. Timepoint: Before the start of the study and the first day after hemoperfusion. Method of measurement: CT scan of the patient.

Secondary Outcome Measures

Name	Time	Method
Temperature. Timepoint: Days 1, 3, 7 and 12. Method of measurement: Thermometer.;O2 sat. Timepoint: Days 1, 3, 7 and 12. Method of measurement: Pulse oximetry.;WBC. Timepoint: Days 1, 3, 7 and 12. Method of measurement: Blood test.;Lym. Timepoint: Days 1, 3, 7 and 12. Method of measurement: Blood test.;Ferritin. Timepoint: Days 1, 3, 7 and 12. Method of measurement: Blood test.;Ast, Alt , Alkp. Timepoint: Days 1, 3, 7 and 12. Method of measurement: Blood test.;Mechanical ventilation. Timepoint: Before the intervention and the first dose after hemoperfusion. Method of measurement: Patient prognosis.